Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease‐modifying antirheumatic drugs (bDMARDs) within the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kremer, Joel M., Bingham, Clifton O., Cappelli, Laura C., Greenberg, Jeffrey D., Madsen, Ann M., Geier, Jamie, Rivas, Jose L., Onofrei, Alina M., Barr, Christine J., Pappas, Dimitrios A., Litman, Heather J., Dandreo, Kimberly J., Shapiro, Andrea B., Connell, Carol A., Kavanaugh, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966883/
https://www.ncbi.nlm.nih.gov/pubmed/33570260
http://dx.doi.org/10.1002/acr2.11232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966883/
https://www.ncbi.nlm.nih.gov/pubmed/33570260
http://dx.doi.org/10.1002/acr2.11232

Ejemplares similares